BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program

Core Insights - BioRestorative Therapies, Inc. has received a notice of allowance from the Japanese Patent Office for a patent related to its ThermoStem® platform, enhancing its intellectual property portfolio [6][7] - The company is actively expanding its ThermoStem® intellectual property estate to secure long-term market exclusivity for its BADSCs, which are aimed at treating obesity and metabolic disorders [2][11] - BioRestorative is engaged in substantive discussions with a commercial stage regenerative medicine company regarding a potential licensing agreement for its ThermoStem® metabolic intellectual property [12] Company Overview - BioRestorative develops therapeutic products using adult stem cells, focusing on two main clinical programs: treatment of disc/spine disease and metabolic disorders [3] - The company operates a commercial BioCosmeceutical platform, offering a cell-based secretome product designed to reduce fine lines and wrinkles, with plans to expand its product line [4] Metabolic Program - The ThermoStem® program utilizes brown adipose derived stem cells (BADSC) to generate brown adipose tissue (BAT), which is linked to increased caloric burning and reduced glucose and lipid levels [9] - Preclinical studies indicate that BADSCs can lead to significant reductions in weight, triglyceride, and blood glucose levels in animal models [11] Disc/Spine Program - The lead therapy candidate, BRTX-100, is formulated from a patient's own mesenchymal stem cells and is intended for non-surgical treatment of lumbosacral disc disorders [13] - A Phase 2 clinical trial for BRTX-100 has commenced, targeting chronic lower back pain due to degenerative disc disease [13]